Abstract
As countries emerge from pandemic lockdown, many countries are relaxing international travel restrictions. Commercially available serologic tests for anti-SARS-CoV-2 antibodies are being performed. The concept of an 'immunity passport' has gained popularity, whereby evidence of SARS-CoV-2 antibody production would signal immunity to reinfection. For an immunity certificate to be validated for travel purposes, it should meet certain criteria. The introduction of such certificates faces multiple challenges. While there may be a future role for immunity passports in limited circumstances in the event that a protective vaccine becomes freely available, for now at least the risks of such an approach outweigh the perceived benefits.
| Original language | English |
|---|---|
| Pages (from-to) | E135-E136 |
| Journal | Journal of Public Health (United Kingdom) |
| Volume | 43 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Mar 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Infectious disease
- migration
- public health
Fingerprint
Dive into the research topics of 'Immunity passports to travel during the COVID-19 pandemic: controversies and public health risks'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver